Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Atogepant (Qulipta) and ubrogepant (Ubrelvy) are both medications that belong to the calcitonin gene-related peptide (CGRP) receptor blocker class and are used to manage migraines in adults. However, they differ in their specific uses and administration. Atogepant is used to prevent migraines and is taken once daily, while ubrogepant is used to treat sudden migraine attacks and can be taken up to twice a day, with doses at least 2 hours apart. Both medications are only available as brand-name products. Common side effects of atogepant include nausea, constipation, and sleepiness, while ubrogepant may cause nausea, sleepiness, and dry mouth. Both can interact with other medications, so it's important to discuss all medications you're taking with a healthcare professional.
Qulipta (atogepant)
Ubrelvy (ubrogepant)
Qulipta (atogepant)
Ubrelvy (ubrogepant)
Summary of Qulipta vs. Ubrelvy
Summary for Calcitonin gene-related peptide (CGRP) receptor blocker
Prescription only
Qulipta (atogepant) is a medication that's used to prevent migraines in adults. The specific dosing will depend on how many migraines you have per month, but the medication is typically taken once daily. Qulipta (atogepant) is currently brand only; it isn't available as a lower-cost generic yet. Side effects include nausea, constipation, and sleepiness.
Summary for Calcitonin gene-related peptide (CGRP) receptor antagonist
Prescription only
Ubrelvy (ubrogepant) is a migraine medication called a calcitonin gene-related peptide (CGRP) receptor antagonist. It can treat sudden migraine attacks in adults. Ubrelvy (ubrogepant) is a tablet you take by mouth. You take one dose when you feel a migraine starting. If needed, you can take a second dose at least 2 hours later. Your dose depends if Ubrelvy (ubrogepant) interacts with the other medications you take. Side effects include nausea and tiredness.